ribavirin elaidate

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Nameribavirin elaidate
Drug Alias NameRibavirin Derivative (Clavis Pharma)Ribavirin Derivative (Translational Therapeutics)TRX-201CP-4033
ClassificationSmall molecules > Lipid
Mechanisms of ActionEukaryotic translation initiation factor 4E inhibitors
TargetsEukaryotic translation initiation factor 4E
Therapy Area/IndicationsThyroid NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNorway
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAqualis
China Registration ClassN/A

Develop Information

Inactive CompaniesAqualis
Active IndicationsThyroid Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A